Medicenna Therapeutics Corp (MDNA) NPV
Medicenna Therapeutics Corp. is an immunotherapy company. The Company is engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) tunable cytokines, called Superkines and Empowered Superkines (ECs). It focuses on commercialization of EC and Superkines for the treatment of cancer and other diseases. The Company’s Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform allows to develop designer Superkines by combining them to other proteins, antibodies or naked IL-2, IL-4 and IL-13 Superkines to combine two distinct and synergistic mechanisms of action into one molecule. The Company’s product candidates MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. It is being developed as a therapeutic for various solid tumors in combination with other immunotherapies.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.